HLTT

Healthtech Solutions, Inc., through its subsidiaries, operates as a life sciences company. It focuses on the development of wound care products for acute and chronic wounds, including AmnioBind, a placental membrane allograft for burns and non-healing wounds, such as diabetic foot ulcers. The company also engages in the development of ultrasound imaging and artificial intelligence-based image analysis software for the applications in treatment of chest and musculoskeletal system. In addition, it is developing software technology that compares a healthy heart rhythm electronic signal with a damaged heart's signal that derives an electronic signal representing the curative waveform. The company was founded in 2018 and is based in Tuckahoe, New York.